- Home
- CITE vs PLX Comparison
CITE vs PLX Comparison
Compare CITE & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CITE
- PLX
- Stock Information
- Founded
- CITE 2021
- PLX 1993
- Country
- CITE United States
- PLX Israel
- Employees
- CITE N/A
- PLX N/A
- Industry
- CITE
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CITE
- PLX Health Care
- Exchange
- CITE NYSE
- PLX Nasdaq
- Market Cap
- CITE 92.2M
- PLX 79.4M
- IPO Year
- CITE 2022
- PLX 1998
- Fundamental
- Price
- CITE $11.55
- PLX $1.68
- Analyst Decision
- CITE
- PLX
- Analyst Count
- CITE 0
- PLX 0
- Target Price
- CITE N/A
- PLX N/A
- AVG Volume (30 Days)
- CITE 22.8K
- PLX 439.0K
- Earning Date
- CITE 01-01-0001
- PLX 11-14-2024
- Dividend Yield
- CITE N/A
- PLX N/A
- EPS Growth
- CITE N/A
- PLX N/A
- EPS
- CITE N/A
- PLX N/A
- Revenue
- CITE N/A
- PLX $45,667,000.00
- Revenue This Year
- CITE N/A
- PLX N/A
- Revenue Next Year
- CITE N/A
- PLX $88.94
- P/E Ratio
- CITE N/A
- PLX N/A
- Revenue Growth
- CITE N/A
- PLX N/A
- 52 Week Low
- CITE $10.79
- PLX $0.82
- 52 Week High
- CITE $12.25
- PLX $1.90
- Technical
- Relative Strength Index (RSI)
- CITE 65.68
- PLX 74.56
- Support Level
- CITE $11.53
- PLX $1.14
- Resistance Level
- CITE $11.57
- PLX $1.75
- Average True Range (ATR)
- CITE 0.01
- PLX 0.12
- MACD
- CITE 0.00
- PLX 0.05
- Stochastic Oscillator
- CITE 85.72
- PLX 87.29
About CITE CARTICA ACQUISITION CORP
Cartica Acquisition Corp is a blank check company.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.